ZM96GPN

ZM96GPN is a **DNA vaccine** candidate designed for the prevention of HIV infection. It consists of a plasmid encoding a **Gag-Pol-Nef (GPN)** fusion protein derived from the **HIV-1 clade C** isolate **96ZM651.8**. Developed by the **UK HIV Vaccine Consortium (UKHVC)** and **Imperial College London**, ZM96GPN is typically utilized as a priming agent in heterologous prime-boost immunization strategies. In clinical trials, such as the Phase I **UKHVC Spoke 003** study (NCT01922284), ZM96GPN is administered alongside **CN54ENV** (a plasmid encoding the HIV-1 Env protein) to prime the immune system, followed by booster vaccinations with viral vectors (e.g., Modified Vaccinia Ankara/MVA-C) and recombinant proteins (e.g., CN54rgp140). The vaccine facilitates the endogenous production and presentation of essential HIV-1 structural and regulatory antigens to stimulate robust cellular and humoral immune responses targeting the clade C virus, which is prevalent in sub-Saharan Africa.

Other names

96ZM651-8 Gag-Pol-Nef DNA plasmidZM96 Gag-Pol-Nef plasmidZM-96 Gag-Pol-Nef plasmidZM 96 Gag-Pol-Nef plasmidGag-Pol-Nef DNA plasmid